Beckley Psytech Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Beckley Psytech Limited
The psychedelics sector has been hit hard by lack of funding options of late but the prospects for Eleusis, which had to terminate a SPAC merger in the summer, look brighter with its acquisition by Beckley Psytech.
One of the best-attended sessions at the BIO meeting in San Diego saw psychedelics specialists weighing up the sector's chances of breaking taboos and getting to market.
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.
The Danish diabetes titan teams with Moderna’s founder on cardiometabolic R&D. Troubled cell therapy biotech Bone Therapeutics negotiates reverse merger with Medsenic.
- Drug Delivery
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.